Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Use of emerging testing technologies and approaches for SARS-CoV-2: review of literature and global experience in an Australian context

MARYZA GRAHAM1,2, SUSAN A. BALLARD1, SHIVANI PASRICHA3, BELINDA LIN1, TUYET HOANG1,3, TIMOTHY STINEAR1, JULIAN DRUCE1, MIKE CATTON4, NORELLE SHERRY1,5, DEBORAH WILLIAMSON1,3,5, BENJAMIN P. HOWDEN1,3

1Microbiological Diagnostic Unit, Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; 2Department of Microbiology and Infectious Diseases, Monash Health, Clayton, Vic, Australia; 3Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; 4Victorian Infectious Diseases Reference Laboratory, Melbourne Health at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; 5Department of Microbiology, Royal Melbourne Hospital, Parkville, Vic, Australia

Summary
Emerging testing technologies for detection of SARS-CoV-2 include those that are rapid and can be used at point-of-care (POC), and those facilitating high throughput laboratory-based testing. Tests designed to be performed at POC (such as antigen tests and molecular assays) have the potential to expedite isolation of infectious patients and their contacts, but most are less sensitive than standard-of-care reverse transcription polymerase chain reaction (RT-PCR). Data on clinical performance of the majority of emerging assays are limited with most evaluations performed on contrived or stored laboratory samples. Further evaluations of these assays are required, particularly when performed at POC on asymptomatic patients and at various time-points after symptom onset. A few studies have so far shown several of these assays have high specificity. However, large prospective evaluations are needed to confirm specificity, particularly before the assays are implemented in low prevalence settings or asymptomatic populations. High throughput laboratory-based testing includes the use of new sample types (e.g., saliva to increase acceptability) or innovative uses of existing technology (e.g., sample pooling). Information detailing population-wide testing strategies for SARS-CoV-2 is largely missing from peer-reviewed literature. Logistics and supply chains are key considerations in any plan to ‘scale up’ testing in the Australian context. The strategic use of novel assays will help strike the balance between achieving adequate test numbers without overwhelming laboratory capacity. To protect testing of high-risk populations, the aims of testing with respect to the phase of the pandemic must be considered.

Key words: Testing; COVID-19; SARS-CoV-2.

Received 3 May, revised 12 July, accepted 3 August 2021
Available online 10 August 2021

INTRODUCTION
As the COVID-19 pandemic has progressed and diagnostic needs have evolved, a range of emerging testing technologies for detection of SARS-CoV-2 have become available. These include rapid diagnostic and point-of-care (POC) tests and those facilitating high-throughput laboratory-based testing. The quality of the evaluations for emerging tests are variable and often insufficient, especially for performance related to the intended use.1–3 The majority of available information regarding emerging tests and testing strategies is derived from high-prevalence scenarios and the relevance to the Australian context is unclear. We summarise the currently available information for emerging testing strategies and technologies to elucidate their potential use in the Australian context.

IDENTIFYING TESTING APPROACHES USING MODELLING
The characteristics of emerging assays relative to standard laboratory-based reverse transcription polymerase chain reaction (RT-PCR) vary considerably with respect to performance, turnaround time (TAT) and throughput (Table 1). Mathematical modelling studies examining the relative contributions of various testing strategies show that approaches with high test numbers and short TAT have the greatest impact.4–6

Modelling has shown that minimising testing delay had the largest impact on reducing onward transmissions and optimising testing coverage further enhanced contact tracing effectiveness.6 Keeping the time between symptom onset and testing and isolation of an index case at 2 days or less is imperative for success in reducing the reproductive number, noting that rapid testing of symptomatic people is at least as important as the efficiency of contact tracing.7 Weekly PCR screening of healthcare workers (HCWs) and other high-risk groups, irrespective of symptoms was estimated to reduce their contribution to SARS-CoV-2 transmission (R) by 23%.5

Print ISSN 0031-3025/Online ISSN 1465-3931 Crown Copyright © 2021 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). DOI: https://doi.org/10.1016/j.pathol.2021.08.001
This reduction is in addition to the reductions achieved when people self-isolate following symptoms, assuming test results are available at 24 hours. A 15% reduction in test sensitivity reduces the effectiveness of weekly screening from 23% to 19%. If 80% of cases and contacts are identified and there is immediate testing following symptom onset and quarantine of contacts occurs within 24 hours, R can be reduced by 26%. This result is on top of reductions achieved by self-isolating following symptoms. For 50% coverage and a 48-hour delay in quarantining, the reduction in transmission is just 8%.

One model found that effective screening depends largely on testing frequency and the speed of reporting and is only marginally improved by high test sensitivity. A notable assumption in this model is that during the exponential growth phase of the virus, the time between 10^3 and 10^5 copies/mL is short, allowing a limited window in which only the more sensitive test could diagnose individuals. A limitation of this study is it did not consider test specificity: specificity considerations must be taken into account. Individuals with low levels of SARS-CoV-2 in their respiratory secretions are more likely to be infectious than those with low levels, but whether lower-sensitivity tests can reliably detect persons who are likely to be infectious remains to be proven. It is clear that samples with lower PCR cycle threshold (Ct) values are more likely to contain SARS-CoV-2 that can be detected in viral culture, but there is no clear separation among samples that are culture positive or not when using the Ct value. Furthermore, there remain no robust clinical data linking viral quantity to transmissibility.

Fundamentally, optimisation of SARS-CoV-2 testing is paramount to controlling the pandemic. Here we summarise the current literature for emerging testing technologies and approaches and discuss their potential in the Australian context. We have included peer-reviewed literature, independent evaluations and selected widely-cited pre-prints.

### INNOVATIONS IN MOLECULAR ASSAYS

#### Commercial point-of-care (POC) or near-POC molecular assays

Commercial POC rapid nucleic acid amplification techniques (NAATs) fall into two categories: those with instrumentation widely available in Australia and those where instrumentation is less available (Table 2). Of the former group, the Xpert Xpress SARS-CoV-2 assay has shown reliable performance but has had severe limitations on test cartridge supply. Therefore, there is a need to investigate the performance of alternative assays for which there are less available data.

A March 2021 Cochrane review found that sensitivities of rapid molecular assays varied according to test brand. Most of the data relate to the ID NOW COVID-19 (Abbott) and Xpert Xpress (Cepheid) assays. Using data from evaluations following the instructions for use (IFU), the average sensitivity of ID NOW was 73.0% [95% confidence interval (CI) 66.8–78.4%] and average specificity 99.7% (95% CI 98.7–99.9%). For Xpert Xpress, the average sensitivity was 100% (95% CI 88.1–100%) and average specificity 97.2% (95% CI 89.4–99.3%). A Foundation for Innovative New Diagnostics (FINDx) independent evaluation determined the Xpert assay had 100% sensitivity and 99% specificity when compared to the Cobas assay (Roche) which is widely used in Australia.

The variable performance in sensitivity of the ID NOW SARS-CoV-2 assay may be attributed to the type of swab used, the time of testing following onset of symptoms and the reference assay used in the different studies. Several of the early evaluations of ID NOW used viral transport media/universal transport media rather than dry swabs, so did not follow the manufacturer’s IFU, thus requiring further evaluation.

### Table 1 Comparison of characteristics of emerging assays relative to standard laboratory-based RT-PCR

| Assay type | Available literature | TAT | Sensitivity | Specificity | Ease of use at POC | Scalability | Cost | Supply chain |
|------------|---------------------|-----|-------------|-------------|-------------------|------------|------|--------------|
| Standard laboratory-based RT-PCR | ++++/++++ | Hours | +++ | +++ | n/a | +++ | +++ | +++/+ |

1. Innovations of molecular assays

- Rapid or near POC RT-PCR: +++ | Under 1 hour | +++ | +++ | ++ | +++ | +/+/ |
- POC NAAT: ++/++ | Minutes | +++/+ | +++ | ++++ | + | +++ | +/++ |
- Extraction-free LAMP: ++/++ | Minutes–hours | +++/+ | ++++/+++ | + | ++ | +++ |
- Saliva RT-PCR: ++/++ | Hours | +++/+ | +++ | n/a | +++ | +++ | +++ |
- Pooling: ++ | Hours | +++ | +++ | n/a | ++++ | + | ++ |
- Extraction-free RT-PCR: + | Hours | +++ | +++ | n/a | ++++ | + | ++ |
- RT-PCR with WGS: – | Hours–days | – | – | – | –/+++ | +++ | – |

2. Non-molecular assays

- POC Antigen: ++++ | Minutes | ++++/+++ | ++++/++++ | ++ | + | –/++ |

3. Emerging technology

- CRISPR: + | Hours | +++ | +++ | – | – | + | – |
- Microfluidics: – | Hours | –/– | – | – | – | – |
- Virolens: – | Seconds | – | – | – | – | – |

4. Antibody assays

- POC Antigen: ++ | Minutes | +/- | ++ | +++ | + | ++++ |

---

- -, unknown/insufficient data; +, minimal; ++, moderate; ++++, high; ++++, very high; n/a not applicable; CRISPR, clustered regularly interspaced short palindromic repeats; LAMP, loop-mediated isothermal amplification; NAAT, nucleic acid amplification techniques; POC, point-of-care; RT-PCR, reverse-transcription polymerase chain reaction; TAT, turnaround time; WGS, whole genome sequencing.

---

690 Grahame et al.
Pathology (2021), 53(6), October
To allow comparison of analytical performance of different molecular assays, the US Food and Drug Administration (FDA) developed a SARS-CoV-2 Reference Panel. Results of various concentrations of inactivated SARS-CoV-2 as blinded samples for a number of different POC molecular assays are shown in Supplementary Table 1 (Appendix A).

Other TGA listed POC or near-POC assays with significant performance data available in peer-reviewed literature and showing similar performance to Xpert assay include the Liat (Roche) and the FilmArray (BioFire).

Loop-mediated isothermal amplification (LAMP)

LAMP was developed as a rapid and cheap method to amplify DNA/RNA target at a single reaction temperature, bypassing the need for sophisticated thermal cycling equipment. Several studies have evaluated various novel LAMP methods for SARS-CoV-2 using extraction-free methods, with results available within minutes. Extraction of RNA improves sensitivity approaching that of laboratory-based RT-PCR but increases testing complexity, TAT and the need for extraction reagents, which at times during the pandemic have been in short supply. This rapid assay can potentially be used at POC with medium throughput capability. Currently, there are limited studies on LAMP at POC; therefore, its feasibility, particularly with and without an extraction step, requires further study.

Saliva testing

Collecting saliva specimens for SARS-CoV-2 testing has several advantages over nasopharyngeal swab (NPS): less patient discomfort, is amenable to self-collection and poses less risk to HCWs. There are 17 US FDA Emergency Use Authorisation assays for SARS-CoV-2 RNA detection in saliva: four are authorised for use in asymptomatic populations. The limit of detection (LOD) for evaluated assays ranges from 600 NDU/mL to 180,000 NDU/mL in FDA Reference Panel data, but limited clinical performance evaluations are available. There are currently three TGA approved COVID-19 tests (NeumoDx, PerkinElmer and Seegene) for use with saliva, meaning that most Australian laboratories are required to perform their own validation of assays for saliva testing.

Six published meta-analyses using various RT-PCR assays have generally found saliva testing to be less sensitive than testing of nasopharyngeal swabs. Studies using saliva testing for SARS-CoV-2 detection have employed various collection methods, processing methods, assays and patient populations and therefore have yielded variable results. Two studies testing saliva samples used the Xpert assay. In one, there was good correlation with validated assays in a mix of emergency department (ED), inpatients and outpatients with positive agreement (PPA) of 98.9% (87/88 specimens) and negative agreement (NPA) of 100%. The other found good correlation with paired NPS in ED...
and suspected COVID-19 patients, with a PPA of 96% (47/49 patients) and NPA of 99%.41

Given the advantages of saliva testing, and as several reasonably sized studies show moderately high sensitivity, further studies are warranted to evaluate the optimum specimen collection and processing methods for saliva testing. In the interim, the current Australian Testing Framework (updated 25 June 2021) states that Australian laboratories are using saliva samples for RT-PCR to facilitate expanded surveillance, but that saliva sample testing is not intended to replace well validated, gold-standard swab-based RT-PCR for diagnosis of disease in symptomatic people.42

Currently there are very few clinical validation studies on the use of saliva, as sample material for rapid antigen tests and data on the sensitivity of the tests are lacking.43 Limited available information suggests poor sensitivity compared to nasal swabs.44

Sample pooling
testing pooled specimens rather than individual testing saves on resources and time.34,40 The European Centre for Disease Prevention and Control (ECDC) guidelines suggest large-scale population-wide testing by means of pool-based strategies.35,37 The disease prevalence in a population affects the efficiency of pooled testing strategies, with lower prevalence potentially enabling a larger pool size. The US Centers for Disease Control and Prevention (CDC) found that NAT for SARS-CoV-2 reliably returned a positive result when one positive sample was mixed with four negatives and could reduce the number of tests needed by >50% in scenarios such as COVID-19 prevalence of <5%.38 As pooled specimens are diluted when the pool is larger, there is a higher likelihood of generating false-negative results so monitoring prevalence is also important to limit this.39

Extraction-free RT-PCR
The extraction step of RT-PCR improves sensitivity by purifying DNA/RNA. The advantages of extraction-free PCR are that it is rapid, cost-effective and not reliant on extraction reagents that have been in short supply. The main disadvantage of extraction-free RT-PCR is reduction in sensitivity, which ranges between 81.3 and 94.6%.30–32

RT-PCR with whole-genome sequencing (WGS)
WGS of SARS-CoV-2 can improve the resolution of outbreak clusters. It can better define possible transmission networks and therefore inform public health responses. Combining diagnostic testing with WGS has the potential to improve TAT for the genomics results since high throughput detection of SARS-CoV-2 can be combined with WGS of positive samples such as with COVIDSeq assay (Supplementary Table 2, Appendix A).33–36

ANTIGEN TESTS
There is a paucity of peer-reviewed literature evaluating the clinical performance of the various antigen assays, particularly in low-prevalence settings (Table 3). A 2020 Cochrane review found the sensitivity of included antigen tests (Beijing Savant, Coris Bioconcept, Liming Bio, RapiGEN, Shenzhen Bioeasy and one in-house assay) varied considerably across studies. Based on five studies (n=943), the average sensitivity was 56.2% (95% CI 29.5–79.8%) and average specificity was 99.5% (95% CI 98.1–99.9%). Data for individual antigen tests were limited, with no more than two studies for any test. This review identified that early evaluations of POC tests are largely based on remnant laboratory samples. It is uncertain whether tests will perform similarly in clinical practice, and with regards to symptom type, duration of symptoms, or in asymptomatic people.8

A March 2021 update to the Cochrane review found that estimates of antigen sensitivity varied considerably between studies and between brands. There were differences between symptomatic (72.0%, 95% CI 63.7–79.6%) and asymptomatic participants (58.1%, 95% CI 40.2–74.1%). Average sensitivity was higher in the first week after symptom onset (78.3%, 95% CI 71.1–84.1%) than in the second week of symptoms (51.0%, 95% CI 40.8–61.0%). Using data from manufacturer’s instructions for use (IFU) compliant evaluations in symptomatic participants, summary sensitivities ranged from 34.1% (95% CI 29.7–38.8%; Coris Bioconcept) to 88.1% (95% CI 84.2–91.1%; SD Biosensor STANDARD Q). Average specificities were high in symptomatic and asymptomatic participants, and for most brands (overall summary specificity 99.6%, 95% CI 99.0–99.8%).8

Of the 13 TGA approved antigen tests, the Panbio COVID-19 Ag rapid test (Abbott) currently has the most peer-reviewed literature, including for children.37–38 Two early studies of the Panbio COVID-19 Ag rapid test found sensitivity between 73–81% and 100% specificity.61,62 In addition, FINDdx independent evaluations found Panbio sensitivity for NPS in symptomatic persons to be 85.5% (95% CI 78.2–90.6%) with clinical specificity of 100% (95% CI 99.1–100%). An Australian multi-site assessment of the Panbio antigen test in a low-prevalence setting found a specificity of 99.96% in 2413 individuals (95% CI 99.73–100%).69

Of the other TGA approved antigen tests, the SD Biosensor Standard Q (supplied in Australia by Roche Diagnostics) also has a significant amount of peer-reviewed literature.66,68,70–73 FINDdx evaluation found sensitivities for NPS in symptomatic persons between 88.7–89% with specificity 97.6–99.7%.36

Continuously emerging results from FINDdx independent evaluations are likely to substantially inform performance in real-life scenarios (Table 4).74 For example, recent FINDdx results comparing performance of nasal swabs (NS) to NPS found for the the PanBio antigen test a sensitivity of 86.4% (95% CI 73.3–93.9%) for NS and 90.9% (95% CI 78.8–96.4%) for NPS in a small study with 44 positive cases; for SD Biosensor a sensitivity of 80.5% (95% CI 66.0–89.8%) for NS and 73.2% (95% CI 58.1–84.3%) for NPS in 41 positive patients; and for NowCheck a sensitivity of 89.9% (95% CI 81.3–94.8%) for both NS and NPS in 79 positive patients.

OTHER NOVEL EMERGING TECHNOLOGIES
CRISPR
Two assays for detection of SARS-CoV-2 RNA combining isothermal amplification and CRISPR technology have been approved by the US FDA; SHERLOCK and DETECTR (Mammot Biosciences). The SHERLOCK assay is portable, and testing can be performed on a heat block or water bath. CRISPR assay reagents can cost <$1 per test.77
Detection can be performed by lateral flow assay (portable, read by eye) or fluorescence. The reaction TAT for the SHERLOCK assay is 1 hour, whereas it is 45 minutes for the DETECTR assay. According to the IFU, the DETECTR assay LOD is 12,000 copies/mL UTM. The SHERLOCK assay was included in the recent FDA Reference Panel testing and LOD was found to be 6000 NDU/mL, which was more sensitive than the CDC assay (Supplementary Table 1, Appendix A).

Overall, available information suggests CRISPR may be less sensitive when compared to most commercial RT-PCR.

However, studies have shown specificity between 71.4% and 98.5% for CRISPR. 87,88 so further evaluations are required since a recent review has concluded that although CRISPR technology is still in its infancy it is potentially revolutionary as tests are rapid and portable. 89

Microfluidics
Currently there is one FDA approved assay for SARS-CoV-2 detection in saliva using microfluidics: Advanta Dx (Fluidigm Corporation). Saliva is a validated sample type

Table 3 Peer-reviewed literature for TGA listed SARS-CoV-2 antigen tests (as of 12 April 2021)

| Assay                                      | TAT, minutes | Specimen type | Sensitivity/PPA (n=positive samples/95% CI) | Specificity/NPA (n=negative samples/95% CI) | References |
|--------------------------------------------|--------------|---------------|--------------------------------------------|---------------------------------------------|------------|
| Assure Tech Antigen Rapid Test Device      | 15           | NPS/OPS       | –                                          | –                                           |            |
| BD Veritor System for rapid detection      | 15           | NS            | 76.3% (n=38)                                | 98.8% (n=1268)                              | 113        |
| BIOHIT Antigen Rapid Test Kit             | 15           | –             | –                                          | –                                           |            |
| BCTXN Antigen Rapid Test Kit              | 15           | NPS/OPS       | –                                          | –                                           |            |
| Carestart Antigen/Atomo Antigen Test       | 10           | NS/NPS        | Adults 84.8% (71.1–93.7)                    | Adults 97.2% (92.0–99.4)                     | 115        |
| GenBody Ag                               | 15           | NPS           | Children 85.7% (42.1–99.6)                  | Children 89.5% (66.9–98.7)                   | (preprint) |
| InnoScreen Antigen Rapid Test Device       | 15           | NS/NPS/OPS/NA | –                                          | –                                           |            |
| NowCheck Antigen Test                     | 15–30        | NS/NPS        | 89.2% (81.7–93.9), n=102                    | 97.3% (94.8–98.6)                           | 9          |
| OXIS Ag Point of care test                | 15           | NS/NPS        | 55.6% (21.2–86.3), n=9                     | 100% (99.7–100), n=1317                     | 116        |
| Abbott Panbio Ag Rapid Test Device         | 15–20        | NPS           | 89.9% (81.3–94.8), n=79                    | 98.6% (94.9–99.6), n=139                    |            |
| Asymptomatic contacts                     |              |               | 85.5% (78.2–90.6), n=124                   | 100% (99.1–100), (n=411)                    | 9          |
| Asymptomatic patients                     |              |               | 88.6% (79–92), n=106                       | 99.9% (99.4–100), (n=1002)                  | 61         |
| NPS in saline 83% (n=158)                 |              |               | 76.2% (64.5–79.9)                          | 100% (99.7–100%)                           | 68         |
| Asymptomatic patients                     | 45.4% (n=22) |               | 81.0% (69.0–89.8)                          | 100% (99.7–100%)                           | 62         |
| NPS in saline 83% (n=158)                 |              |               | 73.3% (62.2–83.8)                          |                                              |            |
| SD Biosensor Standard Q Ag Test/           | 15–30        | NPS           | 86.4% (73.3, 93.9), (n=44)                  | 99.2%                                        |            |
| Roche Rapid Antigen Test                  |              |               | 79.8% (n=26)                               | 99.96% (99.73–100%)                        | 69         |
| Asymptomatic contacts                     |              |               | 88.7% (n=106)                              | 97.6%                                        | 9          |
| Asymptomatic patients                     |              |               | 76.6% (n=47)                               | 99.3%                                        | 9          |
| NPS in saline 83% (n=158)                 |              |               | 77.5% (n=191)                              | 99.7%                                        | 9          |
| Asymptomatic patients                     |              |               | 70.0% (n=157)                              | 96% (n=75)                                  | 119        |
| NPS in saline 83% (n=158)                 |              |               | 72.8% (n=149)                              | 99.4%                                        | 72         |
| Asymptomatic patients                     |              |               | 79.5% (64.5–89.2), (n=39)                  | 99.6% (97.8–100)                            | 71         |
| NPS in saline 83% (n=158)                 |              |               | 98.3% (91.06–99.96%), (n=60)               | 98.73% (97.06–99.59%), (n=394)              | 73         |
| Asymptomatic patients                     |              |               | 70.6% (n=109)                              | 100%                                         | 67         |
| NPS in saline 83% (n=158)                 |              |               | 71.4% (NPS & OPS)                          | 99.97% (99.9–100%)                         | 74         |
| Asymptomatic patients                     |              |               | 70.0% (60–79)                              | 92% (87–96)                                 | 75         |
| NPS in saline 83% (n=158)                 |              |               | 89.0% (83.7–93.1), (n=191)                 | 99.7% (98.4–100)                            | 65         |
| Asymptomatic patients                     |              |               | 74.4% (58.9–85.4), (n=29)                  | 99.2% (97.1–99.8)                           | 71         |
| NPS in saline 83% (n=158)                 |              |               | 77.0% (n=61)                               | 99.6% (n=285)                               | 120        |
| Asymptomatic patients                     |              |               | 80.0% (n=40)                               | 98.9% (n=187)                               | 121        |
| Quidel Sofia Antigen FIA                  | 15           | NS            | 74.4% (58.9–85.4), (n=29)                  | 99.2% (97.1–99.8)                           | 71         |
| VivaDia Ag Rapid Test                     | 15           | NS/OPS        | –                                          | –                                           |            |
| NPS in saline 83% (n=158)                 |              |               | 100% (n=40)                                |                                              | 118        |

NA, nasal aspirate; NPA, negative agreement; NPS, nasopharyngeal swab; NS, nasal swab; OPS, oropharyngeal swab; PPA, positive agreement; TAT, turnaround time; 95% CI, 95% confidence interval.

Nil peer-reviewed literature in PubMed or independent evaluation in FINDdx or FDA reference panel.
and the test duration is 2 hours 32 minutes. No published evaluations are currently available. The LOD was 54,000 NAAT detectable units (NDU)/mL in the FDA Comparative Data (Supplementary Table 1, Appendix A).

Virolens
The Virolens system uses a self-administered mouth swab, which is placed inside a cartridge and inserted into a portable tabletop device. Inside the system is a holographic microscope designed to look at nano-scale structures and the light diffracted off the surface of each cell in the sample. This data is run through a computer trained by artificial intelligence to identify the unique pattern of the virus from other cells. The Virolens system is self-contained and can give a result in 20 seconds. Following the first round of field testing carried out in partnership with London Heathrow Airport, Virolens is about to embark on clinical trials (including Heathrow Airport and Leidos in the USA). The UK Medicines and Healthcare products Regulatory Agency have approved the device and submission has been made to the TGA, however no peer-reviewed performance data are publicly available. Ultra-rapid tests with novel mechanisms of action such as this test may have a unique role in the pandemic, subject to performance evaluations.

Table 4  Foundation for Innovative New Diagnostics (FIND) independent evaluations for TGA listed antigen assays (as of 14 April 2021)

| Assay                     | Country          | Reference method       | Antigen test/PCR | Symptoms present [%Yes, (n/N)] | Days from symptom onset [median (Q1–Q3); N] | Clinical sensitivity (95% CI), N    | Sensitivity days ≤7 (95% CI), N | Sensitivity Cl ≤33 (95% CI), N | Sensitivity Cl ≤25 (95% CI), N | Clinical specificity (95% CI), N | Ease of use 86 out of 100 |
|--------------------------|------------------|------------------------|------------------|--------------------------------|---------------------------------------------|-----------------------------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------|
| Bionote NowCheck COVID-19 Ag Test | Brazil           | Various: Cobas, Abbott, etc | NPS or combined NPS/OPS | 100% (382/382) | 4 (3–6), 390 | 89.2% (81.7, 93.9), 102 | 92.2% (84.8, 96.2), 90 | 90.8% (82.9, 95.3), 87 | 94.3% (84.6, 98.1), 53 | 97.6% (95.1, 98.8), 288 |                |
| SD Biosensor STANDARD Q COVID-19 Ag Test | Germany          | Various: Roche Cobas | NPS              | 84.7% (1039/1227) | 3 (2–4), 1002 | 76.6% (62.8, 86.4), 47 | 80.0% (64.1, 90.1), 35 | 87.8% (74.5, 94.7), 41 | 100% (84.5, 100), 21 | 99.3% (98.6, 99.6), 1212 | 98.7% (392/397) |
| Country                  | Reference method | Antigen test/PCR       | Symptoms present | Days from symptom onset | Clinical sensitivity (95% CI), N | Sensitivity days ≤7 (95% CI), N | Sensitivity Cl ≤33 (95% CI), N | Sensitivity Cl ≤25 (95% CI), N | Clinical specificity (95% CI), N | Ease of use 86 out of 100 | |
| Brazil                   | CDC              | NPS                   | 98.7% (392/397) | 5 (4–6), 397 | 88.7% (81.3, 93.4), 106 | 90.7% (83.3, 95.0), 97 | 91.9% (84.9, 95.9), 99 | 95.9% (86.3, 98.9), 49 | 97.6% (95.2, 98.8), 294 | |
| Switzerland              | Roche Cobas      | NPS                   | 64.5% (709/1100) | (79, 92), 106 | 85.5% (78.2, 90.6), 124 | 85.6% (77.9, 90.9), 111 | 100% (99.1,100), 411 | 90.8% (82.2, 95.5), 76 | 99.9% (99.4, 100), 1002 |

CDC, Centers for Disease Control; NPS, nasopharyngeal swab; OPS, oropharyngeal swab.

Breathalysers
Several countries are at various stages of large clinical evaluations of instruments for breath detection of SARS-CoV-2 infection: examples include GeNose, BreathPass, SpiroNose, Brethonix. Detection technologies employed include gas chromatography, different forms of mass spectrometry, and nanosensors to either detect volatile organic compounds or directly detect the virus. There is a paucity of peer-reviewed literature evaluating large-scale clinical performance of the various assays. In May 2021 Singapore’s Health Sciences Authority (HSA) granted provisional authorisation for two COVID-19 breathalysers. One of these, the TracieX Breathalyser is reported to have a sensitivity of 95% and specificity of 97.8% and the HSA will continue to closely monitor the clinical performance of these tests as they are deployed locally. However, another Dutch assay was found to have lower specificity of 82% when tested on asymptomatic persons and not long after it was launched its use was halted by Amsterdam’s Public Health Service after a concern about sensitivity. Assays with good performance would have the potential to rapidly screen large populations as these assays screen individuals within minutes, but assays with high specificity would be more useful in low-prevalence settings such as Australia.
Trained sniffer dogs
A March 2021 World Health Organization (WHO) blueprint has reviewed the global use of sniffer dogs for SARS-CoV-2 detection and found variable sensitivity between 65.4–100% and specificity between 85.2–98%. The blueprint describes that one dog is able to screen 250–300 persons a day. Challenges include the need for standardisation and validation of approaches and difficulties in training dogs in low-prevalence settings.

Environmental testing
Researchers in the Netherlands, France and the USA have demonstrated a correlation between wastewater SARS-CoV-2 concentrations and clinical cases. Some of the results suggested that the RNA concentrations could provide advanced notice of infections (4–7 days) before confirmed cases and retrospective testing has shown that SARS-CoV-2 is present several months before large outbreaks. There is potential to use environmental surveillance for early warning of outbreaks in countries that have already contained transmission but this needs to be considered. Biosafety requirements will depend on the assay used: biosafety cabinets may be required (in addition to personal protective equipment) particularly if virus in samples is not inactivated or if testing is performed in ‘open’ instrumentation or may generate aerosols.

POC antibody tests

The Peter Doherty Institute for Infection and Immunity has so far evaluated 23 different serology-based point of care tests with results on the TGA website. This validation suggests that manufacturers have claimed a better sensitivity compared to that observed in the Doherty Institute studies (when compared to a molecular-based method). The Doherty Institute studies did demonstrate that the sensitivity of most tests improved with increasing duration (i.e., longer time) between sample collection and symptom onset, up to approximately 20–30 days post-symptom onset. The Australian Testing Framework indicates that POC serology tests are not recommended as first line tests for the diagnosis of acute infection and that the role of these tests is uncertain in the context of Australia’s broadly low prevalence setting. These recommendations may change with changing prevalence, vaccination rates and border opening.

OVERSEAS EXPERIENCE AND TESTING STRATEGIES

Information detailing population-wide testing strategies for SARS-CoV-2 is largely missing from the literature. Overall, a variety of strategies are being considered overseas and the relevance of these to the Australian context is unclear. Strategies used in high prevalence settings include a Liverpool testing pilot of over 3000 people using the Innova lateral flow antigen test which missed 60% of infected asymptomatic people, including 33% of those with high viral loads. Of note, Public Health England’s evaluation of the Innova test showed that its sensitivity was 79.2% when used by trained laboratory scientists, 73% when used by trained healthcare staff, but only 57.5% when used by track and trace centre staff employed by the pharmacy chain Boots. Mass antigen testing (of the entire adult population) in Slovakia has generated controversy and a recent modelling study has concluded that while it was impossible to disentangle the precise contribution of infection control measures and mass testing, mass testing is likely to have had a substantial effect in curbing the pandemic. A hospital preprocedural surveillance PCR testing study in Seattle found low rates of positivity despite a community-wide outbreak.

The European Centre for Disease Prevention and Control (ECDC) suggests that rapid antigen tests can contribute to overall COVID-19 testing capacity, especially in situations in which RT-PCR testing capacity is limited and the ECDC agrees with the minimum performance requirements set by the WHO at ≥80% sensitivity and ≥97% specificity.
Strategies used in low-prevalence countries include rapid antigen test pre-event testing, recently introduced in Singapore for large gatherings such as tradeshows, live performances, spectator sports and weddings. The effect of this testing strategy will be of interest to other low-prevalence countries such as Australia. The WHO implementation guide for SARS-CoV-2 rapid antigen tests suggests that appropriate scenarios for their use include outbreak or high-risk scenarios, particularly during widespread community transmission, but only limited use in low-prevalence populations or in asymptomatic individuals.

Australia’s testing strategy is guided by the Communicable Diseases Network Australia (CDNA)/Public Health Laboratory Network (PHLN) Testing Framework. The role of each test is dependent on the ‘Epidemiological Zone’ or phase of the pandemic which takes into account local prevalence and public health objectives of testing in that context. The role of diagnostic tests for symptomatic people (POC molecular, antigen and antibody tests) and screening tests for asymptomatic people (such as breathalysers, wastewater/sewerage surveillance or air sampling) will change depending on the presence and degree of local community transmission as this will affect the predictive value of these tests. For example, The Australian Testing Framework indicates that for Epidemiological Zone 1 (no community transmission) POC RT-PCR tests may be useful in rural and remote communities when rapid TAT is required or that for Epidemiological Zone 3 (community transmission placing burden on response capacity) rapid antigen tests may prove useful as a screening test for individuals in high risk settings where the pre-test probability is high. The Framework recommends that positive antigen tests would require RT-PCR for confirmation. PHLN and CDNA also recommend reflex RT-PCR of suspected COVID-19 cases that return a negative rapid antigen test result. Although for some tests this may require the collection of two swabs, there are emerging data evaluating the performance of using the universal transport media from standard-of-care swabs in the antigen test buffer instead of collecting a second swab.

As the pandemic evolves, with increasing vaccination rates and plans to open Australian borders, the roles of each test will evolve in the context of emerging performance data of the test in each prevalence context.

THE FUTURE OF DIAGNOSTIC TEST DEVELOPMENT

In Australia, the classification of assays as TGA listed or not (Table 2; Supplementary Table 3, Appendix A) will determine their availability for use in Australia. Assays that are not TGA listed but are available overseas, or that have received funding for development, are required to go through an approval process to ensure that minimum quality and performance requirements are met. Various similar processes are in place overseas (e.g., FDA approval for US or CE-marking for Europe). Due to differences in submissions from manufacturers and approval requirements this leads to varying availability of tests between countries.

For example, the US National Institutes of Health (NIH) awarded $248.7 million in contracts to seven diagnostic companies under its first round of the Rapid Acceleration of COVID-19 Diagnostics Initiative. More than 650 applications were submitted and hundreds of experts from government, academia, and industry helped evaluate applications. NIH selected approximately 100 of the best concepts to enter a 1-week evaluation process. Thirty-one of these moved to a 4–6 week period of initial validation. The seven tests to receive this funding were the first to be chosen for scale-up and delivery to the marketplace (Supplementary Table 3, Appendix A). It is hoped that such initiatives may facilitate rapid development and approval of novel diagnostics to enable timely response during emergency scenarios such as the current COVID-19 pandemic.

CONCLUSIONS

New technologies for detection of SARS-CoV-2 are emerging at an unprecedented pace but reliable information on individual assay performance, availability and supply chains is highly variable. Large-scale evaluations of the performance of available assays in the context of intended use are required to inform optimal deployment for control of the pandemic in Australia.

Conflicts of interest and sources of funding: This work was supported by the Australian Government Department of Health Medical Research Future Fund (MRFF) COVID-19 diagnostics grant provided to the Peter Doherty Institute for Infection and Immunity. The authors state that there are no conflicts of interest to disclose.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.pathol.2021.08.001.

Address for correspondence: Dr Maryza Graham, The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Vic, 3000, Australia. E-mail: maryza.graham@unimelb.edu.au

References

1. Freire-Pasquel B, Vega-Marino P, Velez A, et al. Evaluation of nCoV-QS (McCo BioMed) for RT-qPCR detection of SARS-CoV-2 from nasopharyngeal samples using CDC FDA EUA qPCR kit as a gold standard: an example of the need of validation studies. J Clin Virol 2020; 128: 104454.
2. Wang X, Yao H, Xu X, et al. Limits of detection of 6 approved RT–PCR kits for the novel SARS-CoV-2 (SARS-CoV-2). Clin Chem 2020; 66: 977–9.
3. Edson DC, Casey DL, Harmer SE, et al. Identification of SARS-CoV-2 in a proficiency testing program. Am J Clin Pathol 2020; 154: 475–8.
4. Kretzschmar ME, Rozhnova G, Bootsma MCJ, et al. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Infect Dis 2020; 20: e452–9.
5. Grassey NC, Pons-Salort M, Parker EPK, et al. Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study. Lancet Infect Dis 2020; 20: 1381–9.
6. Larrmore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. medRxiv 2020; Sep 8: https://doi.org/10.1101/2020.06.22.20136309.
7. Pettengill MA, McAdam AJ, Can we test our way out of the COVID-19 pandemic? J Clin Microbiol 2020; 58: e02225-20.
8. Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2021; 3: CD013705.
9. FIND. FIND evaluations of SARS-COV-2 assays. Cited 22 Apr 2021. https://www.findx.org/covid-19/sarscov2-eval/
10. Rhoads DD, Cherian SS, Roman K, et al. Comparison of Abbott ID Now, DiaSorin SimpliXa, and CDC FDA emergency use authorization methods for the detection of sars-cov-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. J Clin Microbiol 2020; 58: e00760-20.
Fenollar F, Bouam A, Ballouche M, et al. Evaluation of the Panbio COVID-19 rapid antigen detection test for the screening of patients with COVID-19. J Clin Microbiol 2021; 59: e02589-20.

Merino P, Gujina J, Muñoz-Gallego I, et al. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detecting test for the diagnosis of SARS-CoV-2 infection. Clin Microbiol Infect 2021; 27: 758–61.

Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 in asymptomatic close contacts of COVID-19 patients. Clin Microbiol Infect 2021; 27: e1–4.

Albert E, Torres I, Bueno F, et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect 2021; 27: 472.e7–10.

Gremmels H, Winkel B, Shuurman R, et al. Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. E Clinical Medicine 2021; 31: 100677.

Linares M, Pérez-Tanoura R, Carrero A, et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after onset of symptoms. J Clin Virol 2020; 133: 104569.

González-Donapetry P, García-Clemente P, Blloise I, et al. Think of the children: evaluation of SARS-CoV-2 rapid antigen test in pediatric population. Pediatr Infect Dis J 2021; 40: 385–8.

Lee RA, Hergott HC, Benedetti A, et al. Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. J Clin Microbiol 2021; 59: e02881-20.

Berger A, Nsoga MTN, Pérez-Rodriguez FL, et al. Diagnostic accuracy of two commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in community-based testing centers. PLoS One 2021; 16: e0249921.

Villaverde S, Domínguez-Rodríguez S, Sabrido G, et al. Diagnostic accuracy of the Panbio severe acute respiratory syndrome coronavirus 2 antigen rapid test compared with reverse-transcriptase polymerase chain reaction testing of nasopharyngeal samples in the pediatric population. J Pediatr 2021; 232: 287–94.e1.

Cerutti F, Burdino E, Milia MG, et al. Urgent need of rapid tests for SARS-CoV-2 antigen detection: evaluation of the SD-Biosensor antigen test for SARS-CoV-2. J Clin Virol 2020; 132: 104654.

Barker A. Could a breathalyser help detect COVID-19? Indonesian scientists say they’ve developed one. 11 Jan 2021; cited 12 Apr 2021. https://www.abc.net.au/news/2021-01-02/indonesia-to-use-breathalysers-to-detect-covid-19#axs ResponseEntity

Muhí S, Taylor N, Hoang T, et al. Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: a validation and implementation study. Lancet Reg Health West Pac 2021; 9: 100115.

Krüttgen A, Cornelsen CG, Dreher M, Hornfe WM, Immühl M, Kleines M. Comparison of the Panbio™ COVID-19 rapid antigen test to the real star SARS-CoV-2 RT PCR kit. J Virol Methods 2021; 288: 114024.

Lindner AK, Kausch F, et al. In-house comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected oropharyngeal swab. Eur Respir J 2021; 57: 2003961.

Salvagno GL, Bagni F, D’Inzillo G, Bragantini D, Henry BM, Lippi G. Clinical assessment of the Roche SARS-CoV-2 rapid antigen test. Diagnosis (Berl) 2021; Jan 18: https://doi.org/10.1515/dx-2020-0154.

Charymo C, Kaewpanh B, Tantlieng N, et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. Virol J 2020; 17: 177.

Mak GC, Lau SS, Wong KK, et al. Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus. J Clin Virol 2020; 133: 104684.

Nalumans A, Latalo T, Kayivja J, et al. Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda using nasopharyngeal samples. Int J Infect Dis 2021; 104: 282–6.

Rüskens J, Abarzua MJ, Ibekwe P, et al. Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection. J Clin Virol 2021; 137: 104785.

Gootenberg JS, Abudayyeh OO, Lee JW, et al. CRISPR-powered COVID-19 diagnosis. EClinicalMedicine 2021; 288: 114024.

Huang Z, Tian D, Liu Y, et al. The Foundation for Clinical Medicine. Rapid SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swabs in the home setting. MedRxiv 2020; 2 Feb: 2021.02.14.21251712v1.

The Conversation. Indonesian-made COVID-19 breathalyser sensitivity comparable to RT-PCR. 2 Mar 2021; cited 12 Apr 2021. https://theconversation.com/indonesian-made-covid-19-breathalyser-sensitivity-comparable-to-rt-pcr-155497.

McArthur A. One-minute ‘game changing’ COVID-19 breath test currently being trialled in Dubai. 16 Mar 2021; cited 12 Apr 2021. https://www.mobilehealth.com/mhnews/news/id/231791-game-changing-covid-19-breath-test-currently-being-trialled-dubai.

360dx. NIH awards $249M to seven firms for rapid acceleration of COVID-19 diagnostics. 2020; cited 20 Sep 2020. https://www.360dx.com/research-funding/nih-awards-249m-seven-firms-rapid-acceleration-covid-19-diagnostics-20210908-105497.

World Health Organization. Status of environmental surveillance for SARS-CoV-2 virus: scientific brief. 7 Aug 2020; cited 4 July 2021. https://www.who.int/news-room/commentaries/detail/status-of-environmental-surveillance-for-sars-2019-coronavirus-virus.

O’Reilly KM, Allen DJ, Fine P, et al. The challenges of informative wastewater sampling for SARS-CoV-2 must be met: lessons from polio eradication. Lancet Microbe 2020; 1: e189–90.

Ahmed W, Angle N, Edison I, et al. First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: a proof of concept for the wastewater surveillance of COVID-19 in the community. Sci Total Environ 2020; 728: 138765.

Dietz L, Constant D, Pretz, et al. Exploring integrated environmental viral surveillance of indoor environments: a comparison of surface and bioaerosol environmental sampling in hospital rooms with COVID-19 patients. medRxiv 2021; Mar 26: https://doi.org/10.1101/2021.03.26.21241616.

Goodman Administration Therapeutics. Post-market evaluation of serology-based point of care tests. Oct 2020; cited 21 Sep 2020. https://www.tga.gov.au/post-market-evaluation-serology-based-point-care-tests.

Torpjensen I. Covid-19: how the UK is using lateral flow tests in the pandemic. BMJ 2021; 372: n287.

Wis J. Covid-19: lateral flow tests miss over half of cases, Liverpool pilot data show. BMJ 2020; 371: m4848.

Holt E. COVID-19 testing in Slovakia. J Clin Virol 2021; 21: 32.
104. Pavelka M, Van-Zandvoort K, Abbott S, et al. The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia. Science 2021; Mar 23: eabf9648.

105. Mays JA, Greninger AL, Jerome KR, et al. Preprocedural surveillance testing for SARS-CoV-2 in an asymptomatic population in the Seattle region shows low rates of positivity. J Clin Microbiol 2020; 58: e01193-20.

106. European Centre for Disease Prevention and Control. COVID-19 testing strategies and objectives. 15 Sep 2020; cited 12 Apr 2021. https://www.ecdc.europa.eu/sites/default/files/documents/TestingStrategy_Objective-Sept-2020.pdf

107. Ministry of Health, Singapore. Pre-event testing (PET). 24 March 2021; cited 12 Apr 2021. https://www.moh.gov.sg/covid-19/pet

108. Mina MJ, Peto TE, García-Fiñana M, Semple MG, Buchan IE. Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. Lancet 2021; 397: 1425–7.

109. World Health Organization (WHO). SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests: An Implementation Guide. Geneva: WHO, 2020. https://www.who.int/publications/i/item/9789240017740

110. Soleimani R, Deckers C, Huang T, et al. Rapid COVID-19 antigenic tests: usefulness of a modified method for diagnosis. J Med Virol 2021; May 19: https://doi.org/10.1002/jmv.27094.

111. Creager HM, Cabrera B, Schnaubelt A, et al. Clinical evaluation of the BioFire® respiratory panel 2.1 and detection of SARS-CoV-2. J Clin Virol 2020; 129: 104538.

112. Gibani M, Toumaouz C, Sobhani M, et al. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. Lancet Microbe 2020; 1: e300–7.

113. Pekoz A, Parvu V, Li M, et al. Antigen-based testing but not real-time polymerase chain reaction correlates with severe acute respiratory syndrome coronavirus 2 viral culture. Clin Infect Dis 2021; Jan 20: ciaa1706.